PD
MCID: PRK057
MIFTS: 76

Parkinson Disease, Late-Onset (PD)

Categories: Genetic diseases, Mental diseases, Metabolic diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Parkinson Disease, Late-Onset

MalaCards integrated aliases for Parkinson Disease, Late-Onset:

Name: Parkinson Disease, Late-Onset 58 30 6 39 74
Parkinson Disease 58 25 54 26 76 38 30 56 6 45 41 74
Parkinson's Disease 39 77 54 26 55 44 17
Primary Parkinsonism 54 26 76
Pd 58 26 76
Parkinson Disease, Late-Onset, Susceptibility to 58 13
Late Onset Parkinson's Disease 12 15
Late Onset Parkinson Disease 12 76
Paralysis Agitans 54 76
Park 58 76
Parkinson Disease, Age of Onset, Modifier 58
Susceptibility to Parkinson's Disease 6
Parkinson Disease, Susceptibility to 58
Idiopathic Parkinson Disease 76
Lewy Body Parkinson Disease 76
Shaking Palsy 54
Parkinson's 64

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant
multifactorial

Miscellaneous:
progressive disorder
insidious onset
onset mid to late adulthood
levodopa-responsive


HPO:

33
parkinson disease, late-onset:
Onset and clinical course insidious onset progressive
Inheritance sporadic


Classifications:



Summaries for Parkinson Disease, Late-Onset

NIH Rare Diseases : 54 Parkinson disease (PD) is a neurologic disease that affects the movement. The four main symptoms are tremors of the hands, arms, legs, jaw, or head, specially at rest; rigidity, or stiffness; bradykinesia, or slow movement; and postural instability or inability to find balance. The symptoms start slowly, but progress over time, impairing  everyday activities such as walking, talking, or completing simple tasks. Other symptoms may include emotional problems, trouble swallowing and speaking; urinary problems or constipation; skin problems; sleep problems, low blood pressure when standing up from sitting or lying down (postural hypotension), and inexpressive face. Some people will loose their mental abilities (dementia).   Parkinson disease affects several regions of the brain, especially a region known as "substantia nigra" that helps controlling balance and movement. Most cases of PD are sporadic (with no family history), and with onset around 60 years of age; onset before age 20 years is considered to be juvenile-onset Parkinson disease, and after age 50 years is considered late-onset Parkinson disease. However, in some families, there are several cases of Parkinson disease. Familial cases of Parkinson disease, and maybe some sporadic cases, can be caused by changes (mutations) in several genes, such as: Mutations in the SNCA (PARK1), LRRK2 (PARK8), and VPS35 (PARK17) genes are inherited in an autosomal dominant manner. Mutations in genes PARK2, PARK7, and PINK1 (PARK6) appear to be inherited in a recessive manner. Very rare mutations in the TAF1 gene cause Parkinson disease with X-linked inheritance. Mutations in some genes, including GBA and UCHL1 (PARK 5), do not seem to cause Parkinson disease, but to increase the risk of developing the disease in some families. Autosomal recessive PD have earlier onset than autosomal dominant PD. Some studies suggest that these genes are also involved in early-onset or juvenile PD. However, inheriting a mutation does not always mean that a person will have Parkinson's disease, because there may be other genes and environmental factors determining who will develop Parkinson disease. Treatment is usually based on a medication known as levodopa. Other medication includes bromocriptine, pramipexole, ropinirole, amantadine, rasagiline and safinamide.  Deep brain stimulation (DBS) a surgical procedure where electrodes are implanted into the brain may be useful for some people.Prognosis varies, and while some people become disabled, others will have only minor movement problems. Studies have shown that people with PD who have cognitive impairment, postural hypotension, and sleep problems may have a more rapid progression of the disease.

MalaCards based summary : Parkinson Disease, Late-Onset, also known as parkinson disease, is related to parkinson disease 2, autosomal recessive juvenile and parkinson disease 3, autosomal dominant, and has symptoms including seizures, tremor and constipation. An important gene associated with Parkinson Disease, Late-Onset is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are Parkinson disease and Parkinsons Disease Pathway. The drugs Rasagiline and Apomorphine have been mentioned in the context of this disorder. Affiliated tissues include Brain and Brain, and related phenotypes are hallucinations and abnormal autonomic nervous system physiology

Genetics Home Reference : 26 Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.

OMIM : 58 Parkinson disease was first described by James Parkinson in 1817. It is the second most common neurodegenerative disorder after Alzheimer disease (AD; 104300), affecting approximately 1% of the population over age 50 (Polymeropoulos et al., 1996). (168600)

MedlinePlus : 44 Parkinson's disease (PD) is a type of movement disorder. It happens when nerve cells in the brain don't produce enough of a brain chemical called dopamine. Sometimes it is genetic, but most cases do not seem to run in families. Exposure to chemicals in the environment might play a role. Symptoms begin gradually, often on one side of the body. Later they affect both sides. They include Trembling of hands, arms, legs, jaw and face Stiffness of the arms, legs and trunk Slowness of movement Poor balance and coordination As symptoms get worse, people with the disease may have trouble walking, talking, or doing simple tasks. They may also have problems such as depression, sleep problems, or trouble chewing, swallowing, or speaking. There is no lab test for PD, so it can be difficult to diagnose. Doctors use a medical history and a neurological examination to diagnose it. PD usually begins around age 60, but it can start earlier. It is more common in men than in women. There is no cure for PD. A variety of medicines sometimes help symptoms dramatically. Surgery and deep brain stimulation (DBS) can help severe cases. With DBS, electrodes are surgically implanted in the brain. They send electrical pulses to stimulate the parts of the brain that control movement. NIH: National Institute of Neurological Disorders and Stroke

NINDS : 55 Parkinson's disease (PD) belongs to a group of conditions called motor system disorders, which are the result of the loss of dopamine-producing brain cells. The four primary symptoms of PD are tremor, or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability, or impaired balance and coordination. As these symptoms become more pronounced, patients may have difficulty walking, talking, or completing other simple tasks. PD usually affects people over the age of 60.  Early symptoms of PD are subtle and occur gradually.  In some people the disease progresses more quickly than in others.  As the disease progresses, the shaking, or tremor, which affects the majority of people with PD may begin to interfere with daily activities.  Other symptoms may include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions.  There are currently no blood or laboratory tests that have been proven to help in diagnosing sporadic PD.  Therefore the diagnosis is based on medical history and a neurological examination.  The disease can be difficult to diagnose accurately.   Doctors may sometimes request brain scans or laboratory tests in order to rule out other diseases.

UniProtKB/Swiss-Prot : 76 Parkinson disease: A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

PubMed Health : 64 About parkinson's: Parkinson's is a disease of the nervous system that mostly affects older people. It typically begins after the age of 50. The disease can be very hard to live with because it severely restricts mobility and as a result makes daily activities increasingly difficult. Parkinson's is a progressive disease, which means that in most cases it will continue to gradually get worse. Many people who develop Parkinson’s will require nursing care. There is no cure for the disease and its exact cause is not known, but there are effective treatments that can relieve the symptoms.

Wikipedia : 77 Parkinson''s disease (PD) is a long-term degenerative disorder of the central nervous system that mainly... more...

GeneReviews: NBK1223

Related Diseases for Parkinson Disease, Late-Onset

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 1, Autosomal Dominant Parkinson Disease 15, Autosomal Recessive Early-Onset
Parkinson Disease 12 Parkinson Disease 2, Autosomal Recessive Juvenile
Parkinson Disease 3, Autosomal Dominant Parkinson Disease 4, Autosomal Dominant
Parkinson Disease 6, Autosomal Recessive Early-Onset Parkinson Disease 7, Autosomal Recessive Early-Onset
Parkinson Disease 10 Parkinson Disease 8, Autosomal Dominant
Parkinson Disease 11, Autosomal Dominant Parkinson Disease 13, Autosomal Dominant
Parkinson Disease 14, Autosomal Recessive Parkinson Disease 16
Parkinson Disease 5, Autosomal Dominant Parkinson Disease 17
Parkinson Disease 18, Autosomal Dominant Parkinson Disease 19a, Juvenile-Onset
Parkinson Disease 20, Early-Onset Parkinson Disease 21
Parkinson Disease 22, Autosomal Dominant Parkinson Disease 23, Autosomal Recessive Early-Onset
Juvenile-Onset Parkinson's Disease Early-Onset Parkinson's Disease
Lrrk2-Related Parkinson Disease Vps35-Related Parkinson Disease
Parkinson Disease Type 9 Hereditary Late-Onset Parkinson Disease

Diseases related to Parkinson Disease, Late-Onset via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 926)
# Related Disease Score Top Affiliating Genes
1 parkinson disease 2, autosomal recessive juvenile 34.9 LRRK2 PRKN VPS13C
2 parkinson disease 3, autosomal dominant 34.4 LRRK2 MAPT PRKN
3 hereditary late-onset parkinson disease 34.1 GBA LRRK2
4 postencephalitic parkinson disease 34.0 LRRK2 MAPT
5 corticobasal degeneration 32.8 GBA LRRK2 MAPT
6 multiple system atrophy 1 32.7 LRRK2 MAPT PRKN
7 dementia, lewy body 32.3 GBA LRRK2 MAPT PRKN
8 tremor 31.1 ATXN2 GBA LRRK2 MAPT PRKN
9 dementia 30.9 ATXN2 GBA LRRK2 MAPT PRKN
10 movement disease 30.8 GBA LRRK2 MAPT PRKN
11 early-onset parkinson's disease 30.5 GBA LRRK2 PRKN VPS13C
12 supranuclear palsy, progressive, 1 30.5 LRRK2 MAPT PRKN
13 autosomal dominant cerebellar ataxia 30.4 ATXN2 ATXN8OS TBP
14 parkinson disease 10 30.2 LRRK2 PRKN
15 parkes weber syndrome 12.7
16 parkinson disease 4, autosomal dominant 12.7
17 parkinson disease 15, autosomal recessive early-onset 12.5
18 parkinson disease 23, autosomal recessive early-onset 12.5
19 parkinson disease 11, autosomal dominant 12.5
20 parkinson disease 7, autosomal recessive early-onset 12.5
21 parkinson disease 13, autosomal dominant 12.5
22 parkinson disease 5, autosomal dominant 12.5
23 parkinson disease 14, autosomal recessive 12.4
24 parkinson disease 22, autosomal dominant 12.4
25 parkinson disease 12 12.3
26 parkinson disease, mitochondrial 12.2
27 lrrk2-related parkinson disease 12.2
28 pink1 type of young-onset parkinson disease 12.0
29 parkin type of early-onset parkinson disease 12.0
30 vps35-related parkinson disease 12.0
31 glaucoma-related pigment dispersion syndrome 11.8
32 prolidase deficiency 11.8
33 pendred syndrome 11.7
34 waisman syndrome 11.5
35 klippel-trenaunay-weber syndrome 11.5
36 parkinson disease type 9 11.5
37 hypertonia 11.4
38 myoclonus 11.3
39 personality disorder 11.3
40 capillary malformation-arteriovenous malformation 1 11.3
41 von economo's disease 11.3
42 ehlers-danlos syndrome, spondylodysplastic type, 1 11.2
43 swallowing disorders 11.2
44 cervical dystonia 11.2
45 paralysis agitans, juvenile, of hunt 11.2
46 erythroleukemia, familial 11.2
47 capillary malformation-arteriovenous malformation 2 11.2
48 ectodermal dysplasia/skin fragility syndrome 11.1
49 parkinson disease 19a, juvenile-onset 11.1
50 central pain syndrome 11.1

Comorbidity relations with Parkinson Disease, Late-Onset via Phenotypic Disease Network (PDN): (show top 50) (show all 53)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Alzheimer Disease
Anxiety Atypical Depressive Disorder
Autonomic Nervous System Disease Bipolar Disorder
Blepharitis Bronchitis
Bronchopneumonia Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Chronic Myocardial Ischemia Communicating Hydrocephalus
Conjunctivitis Cystitis
Decubitus Ulcer Deficiency Anemia
Delusional Disorder Dependent Personality Disorder
Dysthymic Disorder Early-Onset Generalized Limb-Onset Dystonia
Encephalopathy Erythematosquamous Dermatosis
Esophagitis Fecal Incontinence
Generalized Atherosclerosis Heart Disease
Hypothyroidism Intestinal Volvulus
Iron Deficiency Anemia Leukodystrophy
Major Affective Disorder 9 Major Depressive Disorder
Marasmus Mood Disorder
Neurogenic Bladder Obstructive Hydrocephalus
Osteoporosis Paralytic Ileus
Paranoid Schizophrenia Pernicious Anemia
Personality Disorder Prostatic Hypertrophy
Protein-Energy Malnutrition Pseudobulbar Palsy
Schizophrenia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Parkinson Disease, Late-Onset:



Diseases related to Parkinson Disease, Late-Onset

Symptoms & Phenotypes for Parkinson Disease, Late-Onset

Human phenotypes related to Parkinson Disease, Late-Onset:

33 (show all 24)
# Description HPO Frequency HPO Source Accession
1 hallucinations 33 occasional (7.5%) HP:0000738
2 abnormal autonomic nervous system physiology 33 occasional (7.5%) HP:0012332
3 depressivity 33 HP:0000716
4 dysarthria 33 HP:0001260
5 tremor 33 HP:0001337
6 dysphagia 33 HP:0002015
7 constipation 33 HP:0002019
8 sleep disturbance 33 HP:0002360
9 dystonia 33 HP:0001332
10 mask-like facies 33 HP:0000298
11 rigidity 33 HP:0002063
12 dementia 33 HP:0000726
13 weak voice 33 HP:0001621
14 bradykinesia 33 HP:0002067
15 urinary urgency 33 HP:0000012
16 parkinsonism 33 HP:0001300
17 neuronal loss in central nervous system 33 HP:0002529
18 personality changes 33 HP:0000751
19 postural instability 33 HP:0002172
20 substantia nigra gliosis 33 HP:0011960
21 lewy bodies 33 HP:0100315
22 resting tremor 33 HP:0002322
23 micrographia 33 HP:0031908
24 short stepped shuffling gait 33 HP:0007311

Symptoms via clinical synopsis from OMIM:

58
Neurologic Central Nervous System:
dysarthria
dystonia
rigidity
bradykinesia
shuffling gait
more
Genitourinary Bladder:
urinary urgency

Head And Neck Face:
masked facies

Abdomen Gastrointestinal:
dysphagia
constipation

Neurologic Behavioral Psychiatric Manifestations:
depression

Head And Neck Nose:
decreased sense of smell

Clinical features from OMIM:

168600

UMLS symptoms related to Parkinson Disease, Late-Onset:


seizures, tremor, constipation, angina pectoris, myoclonus, back pain, pain, headache, bradykinesia, hyposmia, syncope, resting tremor, chronic pain, sciatica, sleep disturbances, vertigo/dizziness, equilibration disorder, sleeplessness, muscle rigidity, urgency of micturition

Drugs & Therapeutics for Parkinson Disease, Late-Onset

PubMedHealth treatment related to Parkinson Disease, Late-Onset: 64

Parkinson's is usually treated with medication. At the beginning of the disease – when the symptoms are not problematic – treatment is sometimes not necessary. If the symptoms get worse, medication can help. Treatment with medication generally aims to replace the lacking dopamine. That often relieves symptoms, but does not slow the progress of the disease. Because over time the drugs are no longer effective, the type and dose of medication has to be adjusted again and again. One option is to use a medication pump. It provides the drug either under the skin or directly into the small intestine and ensures a constant supply.Occupational therapy is used to practice everyday movements and activities. Restricted movement means that the muscles lose strength. Movement exercises (physiotherapy) and sports aim to help counteract that and improve movement and coordination. Speech therapy can be an option if the voice becomes quieter and speech less clear.Deep brain stimulation is recommended to some people whose symptoms are not relieved enough by taking medication. That involves surgery to implant electrodes in certain parts of the brain. They continuously emit electrical impulses that influence muscle activity.

Drugs for Parkinson Disease, Late-Onset (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 593)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rasagiline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 136236-51-6 3052776
2
Apomorphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-00-4, 41372-20-7 6005
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
4
Zonisamide Approved, Investigational Phase 4,Phase 2,Phase 3 68291-97-4 5734
5
Donepezil Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 120014-06-4 3152
6
Nicotine Approved Phase 4,Phase 2,Phase 1,Not Applicable 54-11-5 89594 942
7
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
8
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104632-26-0 119570 59868
9
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91374-20-8, 91374-21-9 5095 497540
10
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-92-7 6047
11
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 123441-03-2 77991
12
Amantadine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 768-94-5 2130
13
Rotigotine Approved Phase 4,Phase 3,Phase 2,Phase 1 99755-59-6, 92206-54-7 57537
14
Carbidopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28860-95-9 34359
15
Entacapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130929-57-6 5281081
16
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable 64-17-5 702
17
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2 16590-41-3 5360515
18
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23651-95-8 443940
19
Levetiracetam Approved, Investigational Phase 4,Phase 2 102767-28-2 441341
20
Opicapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 923287-50-7
21
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
22
Midodrine Approved Phase 4,Phase 1,Not Applicable 133163-28-7, 42794-76-3 4195
23
Modafinil Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 68693-11-8 4236
24
Iodine Approved, Investigational Phase 4,Phase 2 7553-56-2 807
25
Galantamine Approved Phase 4,Phase 2,Not Applicable 357-70-0 9651
26
Mirabegron Approved Phase 4 223673-61-8 9865528
27
Cabergoline Approved Phase 4,Phase 3,Not Applicable 81409-90-7 54746
28
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 19982-08-2 4054
29
Lubiprostone Approved, Investigational Phase 4,Not Applicable 136790-76-6 656719
30
Selegiline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 14611-51-9 5195 26757
31
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 57808-66-9 3151
32
Norepinephrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-41-2 439260
33
Bromocriptine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 25614-03-3 31101
34
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
35
Methylphenidate Approved, Investigational Phase 4,Phase 2,Early Phase 1,Not Applicable 113-45-1 4158
36
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 113775-47-6 5311068 68602
37
Trimethobenzamide Approved, Investigational Phase 4,Phase 1 138-56-7 5577
38
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Not Applicable 68-04-2
39
Benserazide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 322-35-0
40
Lithium carbonate Approved Phase 4,Phase 1,Phase 2 554-13-2
41
Verapamil Approved Phase 4 52-53-9 2520
42
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
43
Trandolapril Approved Phase 4 87679-37-6 5484727
44
Atenolol Approved Phase 4 29122-68-7 2249
45
Topiramate Approved Phase 4,Phase 2,Not Applicable 97240-79-4 5284627
46
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
47
Sulfamethazine Approved, Investigational, Vet_approved Phase 4,Not Applicable 57-68-1 5327
48
Promethazine Approved, Investigational Phase 4,Phase 2,Early Phase 1 60-87-7 4927
49
Diphenhydramine Approved, Investigational Phase 4,Phase 2,Early Phase 1 147-24-0, 58-73-1 3100
50
Tetrabenazine Approved, Investigational Phase 4,Phase 3 58-46-8 6018

Interventional clinical trials:

(show top 50) (show all 2632)
# Name Status NCT ID Phase Drugs
1 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status NCT01007630 Phase 4 Rasagiline;Placebo
2 Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease Unknown status NCT02940912 Phase 4 Apomorphine;Placebo
3 An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease Unknown status NCT03034538 Phase 4 Zonegran;Zonegran
4 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
5 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4 nicotine patch;placebo
6 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4 AZILECT®;Placebo
7 Emotion, Mood and Executive Function in Parkinson`s Disease (PD) Unknown status NCT01385735 Phase 4 Rasagiline;Placebo
8 Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease Unknown status NCT02768077 Phase 4 Melatonin(Circadin®);Placebo
9 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status NCT00696215 Phase 4 placebo;rasagiline
10 Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area Unknown status NCT01782638 Phase 4
11 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
12 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
13 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4 Mirapex ER
14 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
15 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4 Strattera;Exelon
16 The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy Unknown status NCT01313819 Phase 4 PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
17 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Unknown status NCT03098368 Phase 4 Rotigotine;Placebo
18 Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Unknown status NCT00142259 Phase 4
19 "Equistasi" and Gait in Hemiparesis Unknown status NCT02714478 Phase 4
20 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
21 Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy Completed NCT01782222 Phase 4 Rotigotine
22 Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease Completed NCT01049984 Phase 4 Rasagiline;Placebo
23 Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease Completed NCT01723228 Phase 4 Rasagiline;Placebo
24 Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off Completed NCT00391898 Phase 4 Levodopa/carbidopa/entacapone;Levodopa/carbidopa
25 Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease Completed NCT00219284 Phase 4 Carbidopa/levodopa/entacapone
26 Mirabegron in Parkinson Disease and Impaired Cognition Completed NCT02536976 Phase 4 mirabegron;Placebo
27 Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms Completed NCT01300819 Phase 4 Rotigotine
28 Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease Completed NCT01018264 Phase 4 solifenacin succinate (VESIcare);placebo
29 Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients Completed NCT01523301 Phase 4 Rotigotine;Placebo
30 A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease Completed NCT01485172 Phase 4 ropinirole monotherapy;placebo monotherapy
31 Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
32 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
33 Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease Completed NCT01168596 Phase 4 Rasagiline;Placebo
34 Virtual Exercises in Patients With Parkinson's Disease. Completed NCT02023034 Phase 4
35 Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit Completed NCT00272688 Phase 4 Levodopa (drug), intraduodenal administration
36 Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain Completed NCT01744496 Phase 4 Rotigotine;Placebo
37 Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management Completed NCT03103919 Phase 4 Rotigotine
38 Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD) Completed NCT00321854 Phase 4 pramipexole
39 Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease Completed NCT00153972 Phase 4 Cabergoline;Levodopa
40 Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease Completed NCT00646204 Phase 4 Memantine;placebo
41 Amitiza in Constipation Associated With PD (Parkinson's Disease) Completed NCT00908076 Phase 4 LUBIPROSTONE
42 Rasagiline and Apathy in Parkinson's Disease Completed NCT00755027 Phase 4 Rasagiline
43 Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States Completed NCT00143026 Phase 4 carbidopa, levodopa, entacapone
44 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
45 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease Completed NCT00640159 Phase 4 Zelapar
46 Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease Completed NCT01313845 Phase 4 amantadine sulfate;0.9% sodium chloride
47 A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery Completed NCT00594464 Phase 4 Rotigotine
48 Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease Completed NCT03022201 Phase 4 DA-9701;Domperidone;Placebo domperidone;Placebo DA-9701
49 Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles Completed NCT01733199 Phase 4
50 Mild Cognitive Impairment in Parkinson's Disease Completed NCT01519271 Phase 4 Exelon Patch (rivastigmine transdermal system);Placebo Patches

Search NIH Clinical Center for Parkinson Disease, Late-Onset

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Parkinson Disease, Late-Onset cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: parkinson disease

Genetic Tests for Parkinson Disease, Late-Onset

Genetic tests related to Parkinson Disease, Late-Onset:

# Genetic test Affiliating Genes
1 Parkinson Disease 30
2 Parkinson Disease, Late-Onset 30 ADH1C ATXN2 ATXN8OS GBA GLUD2 MAPT NR4A2 SNCAIP TBP

Anatomical Context for Parkinson Disease, Late-Onset

MalaCards organs/tissues related to Parkinson Disease, Late-Onset:

42
Brain, Subthalamic Nucleus, Testes, Skin, Bone, Cortex, Spinal Cord
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Parkinson Disease, Late-Onset:
# Tissue Anatomical CompartmentCell Relevance
1 Brain Substantia Nigra pars Compacta Adult Dopaminergic Neurons Affected by disease, potential therapeutic candidate
2 Brain Forebrain White Matter Fibrous Astrocyte Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
4 Brain Neocortex Protoplasmic Astrocyte Cells Potential therapeutic candidate
5 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Parkinson Disease, Late-Onset

Articles related to Parkinson Disease, Late-Onset:

(show top 50) (show all 3607)
# Title Authors Year
1
Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease. ( 29855563 )
2019
2
Anxiety and Levodopa Equivalent Daily Dose Are Potential Predictors of Sleep Quality in Patients With Parkinson Disease in Taiwan. ( 31040814 )
2019
3
Effects of Mindfulness Yoga vs Stretching and Resistance Training Exercises on Anxiety and Depression for People With Parkinson Disease: A Randomized Clinical Trial. ( 30958514 )
2019
4
Pseudo-Ventricular Tachycardia, Pseudo-Atrial Fibrillation, and Pseudo-Atrial Flutter in a Patient With Parkinson Disease: Two's Company, Three's a Crowd. ( 31009038 )
2019
5
Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study. ( 30382389 )
2019
6
Blepharospasm as a Manifestation of Peak of Dose Dyskinesia in Parkinson Disease. ( 30649026 )
2019
7
Frontotemporal dementia risk variant accelerates cognitive decline in Parkinson disease. ( 31036955 )
2019
8
TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. ( 30973966 )
2019
9
Gastrointestinal function in dementia with Lewy bodies: a comparison with Parkinson disease. ( 30741396 )
2019
10
COWAT Performance of Persons with Alzheimer Dementia, Vascular Dementia, and Parkinson Disease Dementia According to Stage of Cognitive Impairment. ( 30746867 )
2019
11
Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect. ( 30615021 )
2019
12
Apolipoprotein E Polymorphisms and Parkinson Disease With or Without Dementia: A Meta-Analysis Including 6453 Participants. ( 30526202 )
2019
13
Challenges in Defining Inappropriate Medication Use in Parkinson Disease Dementia. ( 30285044 )
2019
14
Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease. ( 30285047 )
2019
15
Dysautonomia is associated with structural and functional alterations in Parkinson disease. ( 30796135 )
2019
16
Editors' note: Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease. ( 31036573 )
2019
17
Reader response: Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease. ( 31036574 )
2019
18
Author response: Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease. ( 31036575 )
2019
19
Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease. ( 31036579 )
2019
20
Risk of Parkinson disease in Sjögren syndrome administered ineffective immunosuppressant therapies: A nationwide population-based study. ( 30946325 )
2019
21
Usefulness of a modified questionnaire as a screening tool for swallowing disorders in Parkinson disease: A pilot study. ( 30860108 )
2019
22
Tremor-Dominant in Parkinson Disease: The Relevance to Iron Metabolism and Inflammation. ( 30971879 )
2019
23
Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. ( 31022213 )
2019
24
STN vs. GPi deep brain stimulation for tremor suppression in Parkinson disease: A systematic review and meta-analysis. ( 30177491 )
2019
25
White matter differences between essential tremor and Parkinson disease. ( 30504432 )
2019
26
Substantia nigra hyperechogenicity in essential tremor and Parkinson disease: a longitudinal study. ( 31094036 )
2019
27
Bright light therapy for depression in Parkinson disease: A randomized controlled trial. ( 30770426 )
2019
28
The role of Rab GTPases in the pathobiology of Parkinson' disease. ( 31054512 )
2019
29
Low Vitamin B12 and Parkinson Disease: Potential Link to Reduced Cholinergic Transmission and Severity of Disease. ( 31054604 )
2019
30
Editors' note: Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. ( 31061215 )
2019
31
Reader response: Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. ( 31061216 )
2019
32
Author response: Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. ( 31061217 )
2019
33
Earliest Mechanisms of Dopaminergic Neurons Sufferance in a Novel Slow Progressing Ex Vivo Model of Parkinson Disease in Rat Organotypic Cultures of Substantia Nigra. ( 31064126 )
2019
34
Deep brain stimulation in parkinson disease. ( 31066807 )
2019
35
Differential Aggregation and Phosphorylation of Alpha Synuclein in Membrane Compartments Associated With Parkinson Disease. ( 31068782 )
2019
36
Montreal Cognitive Assessment scale in patients with Parkinson Disease with normal scores in the Mini-Mental State Examination. ( 31073382 )
2019
37
Mitochondrial-Derived Vesicles as Candidate Biomarkers in Parkinson's Disease: Rationale, Design and Methods of the EXosomes in PArkiNson Disease (EXPAND) Study. ( 31091653 )
2019
38
Suicide and suicide attempts after subthalamic nucleus stimulation in Parkinson disease. ( 31101738 )
2019
39
Early- vs late-start levodopa relieved symptoms but did not affect disease progression in Parkinson disease. ( 31108518 )
2019
40
Effectiveness of robot-assisted gait training on freezing of gait in people with Parkinson disease: evidence from a literature review. ( 31110999 )
2019
41
Is High-Spatial-Resolution Diffusion MRI Applicable for the Diagnosis of Parkinson Disease? ( 31112091 )
2019
42
Autonomic dysfunction in Parkinson disease and animal models. ( 30604165 )
2019
43
Effects of a Group Protocol on Physical Activity and Associated Changes in Mood and Health Locus of Control in Adults with Parkinson Disease and Reduced Mobility. ( 30624196 )
2019
44
Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial. ( 30640362 )
2019
45
Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. ( 30640364 )
2019
46
Physiotherapy versus physiotherapy plus cognitive training on cognition and quality of life in Parkinson´s disease: randomized clinical trial. ( 30640726 )
2019
47
Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients: Erratum. ( 30649028 )
2019
48
Mitohormesis and autophagic balance in Parkinson disease. ( 30650065 )
2019
49
New therapeutic developments for Parkinson disease. ( 30651607 )
2019
50
Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in Parkinson Disease: A Randomized, Controlled Study. ( 30657995 )
2019